DermaPure® Saves 18 Year Old's Leg From Frost Bite & is Featured on US TV Programme

DermaPure® Saves 18 Year Old's Leg From Frost Bite & is Featured on US TV Programme

YORK, England, June 1, 2015 /PRNewswire/ --



Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "the Group"), the regenerative
medical devices company, announces that DermaPure(R), which is used in the treatment of
chronic and acute wounds, has been featured in a US TV programme 'The Balancing Act(R)'
highlighting its role in helping to save 18 year old Marty Smithson's leg from frostbite.



http://tissueregenixus.com/balancingact.html



During the programme Dr Marc Robins, specialist in Wound and Hyperbaric Medicine from
Salt Lake City, Utah discusses recent medical advancements, including DermaPure(R), to
manage challenging cases from trauma wounds to treating diabetic foot ulcers. Diabetes
affects 26 million people in the US and 25% of these will develop foot ulcers.



Antony Odell, CEO of Tissue Regenix, commented:



"This programme highlights the tremendous advance represented by DermaPure(R) and its
capacity to heal many types of wounds, including old chronic wounds which are
traditionally more challenging to treat. DermaPure has performed extremely well both in
our study into acute wounds and across many other type of wounds arising from conditions
such as traumatic injury, skin infections, and post-surgical deficits remaining after
cancer removal. The efficacy of DermaPure(R) has been tested in some incredibly tough
cases by clinicians across America and this particular case provides another example of
why we have such confidence in our product."



About Tissue Regenix



Tissue Regenix is a leading medical devices company in the field of regenerative
medicine. The company's patented decellularisation ('dCELL(R)') technology removes DNA and
other cellular material from animal and human tissue leaving an acellular tissue scaffold
which is not rejected by the patient's body which can then be used to repair diseased or
worn out body parts. The potential applications of this process are diverse and address
many critical clinical needs such as vascular disease, heart valve replacement and knee
repair.



Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds.
The company commercialises academic research conducted by our partners around the World.



In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United
States- 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for
its dCELL(R) technology platform.




Tissue Regenix Group Plc: +44(0)19-0443-5176
Antony Odell
Ian Jefferson
Jefferies International Ltd: +44(0)20-7029-8000
Simon Hardy
Harry Nicholas
Tulchan Communications: +44(0)207-353-4200
Tom Buchanan
Victoria Huxster
Matt Low


Tissue Regenix Group Plc


-------
Profile: intent